Six peptides cleared an FDA panel. None of them are legal to compound today.
The agency's advisory committee recommended six of seven peptides for the 503A bulks list. The headlines called it approval. It isn't — and the last substance to clear this committee on the same margin is still waiting, four years on.
On 23 and 24 July, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six of them for the 503A bulks list — the register of substances that compounding pharmacies are permitted to prepare against a prescription.
The six: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. The one rejection: emideltide, better known as DSIP.
Within hours the headlines had it as approval. It isn't. Nothing that happened in July changed what a pharmacy may legally compound today, and on the historical record it may be a long time before it does.
The votes were narrow, and they went against the FDA's own scientists
In each of the six favourable votes, the committee went against the written assessment of the FDA's own reviewers, who had recommended against inclusion. That is unusual but not unprecedented, and it matters for what comes next: the agency now has to decide whether to accept advice that contradicts its own staff.
Three separate legal events, reported as one
Most of the confusion in the coverage comes from merging three distinct steps.
One — removal from Category 2In April 2026 several peptides came off the interim Category 2 list after nominations were withdrawn. This was procedural. It authorised nothing.
Two — a PCAC recommendationThat is what July was. The committee gives a scientific opinion. It does not bind the agency, does not add anything to the bulks list, and does not permit a pharmacy to compound.
Three — placement on the listThis requires the FDA to accept the recommendation and complete notice-and-comment rulemaking. Estimates for that process run from six to eighteen months, and that is the optimistic reading.
Only the third step changes what is legal. It has not happened for any of the six.
The precedent nobody is quoting
In June 2022, the same committee voted 8–5 with one abstention to add glutathione to the final 503A bulks list — over the FDA's own staff recommendation, which had cited thin effectiveness and safety data.
That is almost exactly the margin by which BPC-157 cleared the committee last month, in almost exactly the same posture.
The parallel is worth sitting with, because it is the single most useful data point available for predicting what happens next. A favourable PCAC vote has been a necessary step. On this list, it has not reliably been a sufficient one.
What the panel itself was uneasy about
Two things are worth recording, because they will shape how the FDA treats the recommendations.
The committee was asked to vote on substances whose nominations had already been withdrawn — KPV on day one, and the day-two substances — with the agency reviewing them at its discretion anyway. Several members were visibly unhappy about being asked to rule on substances nobody was formally requesting.
And the committee's composition drew scrutiny, with multiple appointees linked to clinics that provide peptides. HHS has said members passed standard ethics review and that disqualified candidates were removed.
Neither point invalidates the votes. Both are the sort of thing that gets raised if the agency's eventual decision is challenged.
What changes for patients and clinics right now
Nothing.
The peptides a 503A pharmacy may legally compound today remain a short list — sermorelin, glutathione, NAD+ and a handful of others. BPC-157, TB-500, KPV, MOTS-c, epitalon and semax are not on it. Anyone selling them to you today is not selling you a legally compounded prescription medicine, whatever the July headlines implied.
State boards also layer their own rules on top of the federal list, so even after a substance is added, availability will not be uniform.
And if the six are eventually added, truth-in-advertising law still applies. Being compoundable is not being proven. The evidence base for most of these compounds remains thin — which is precisely why the FDA's reviewers recommended against them, and why the votes were close.
What to watch
A second PCAC meeting, covering five further peptides, is expected in February 2027.
For the six recommended in July, the next real signal is whether the FDA opens rulemaking at all. Until a proposed rule appears in the Federal Register, nothing has moved.
Editor's noteThis is the biggest regulatory shift the peptide space has seen in years, and the direction of travel is genuinely toward a legitimate, pharmacy-based pathway. That is worth saying plainly. It is also worth saying plainly that six advisory votes are not a green light, and that anyone telling you otherwise is either not reading carefully or is selling something.
Sources: FDA Pharmacy Compounding Advisory Committee meetings, 23–24 July 2026 and 8 June 2022; Regulatory Affairs Professionals Society; STAT; NPR; Mintz; Alliance for Pharmacy Compounding.
Peptide Curious is published by people with commercial interests in this field, including a peptide manufacturer and a telehealth practice. See our disclosure. Nothing here is medical advice, and nothing here is a recommendation to use any compound.
← All dispatches